Filter the drugs by the phase of research, how they help and the responsive mutations.
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene. Browse the
database of
drugs treating specific mutations compiled by the AIM tool.
| Drug | Marketed as | Description | Phase of research | How it helps |
|---|---|---|---|---|
| 1-EBIO | CFTR potentiator |
Pre-clinical | Restore CFTR Function | |
| 9-aminoacridine | Small molecule CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| ALLN | Proteasome inhibitor preventing premature CFTR breakdown |
Pre-clinical | Restore CFTR Function | |
| ALLO | CFTR corrector and potentiator |
Pre-clinical | Restore CFTR Function | |
| ALX-009 | Bactericidal combination of bovine lactoferrin and hypothiocyanite |
Phase One Clinical Trial | Anti-Infective | |
| AP2M1 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| Acebilustat | Leukotriene A4 hydrolase inhibitor reducing inflammation |
Phase Two Clinical Trial | Anti-Inflammatory | |
| C18 | Small molecule CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| C3 | Small molecule CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| C4 | Small molecule CFTR corrector |
Pre-clinical | Restore CFTR Function |
